Ms. Schulman brings extensive executive leadership, healthcare industry, finance, technology and regulatory and public policy experience through her position as Managing Partner of a large venture capital firm focused on healthcare and biotechnology companies, as well as her previous executive positions with a global biopharmaceutical company and early-stage biopharmaceutical and biotechnology companies. In addition, she has extensive governance and sustainability experience through her positions as a business school lecturer and a former global law firm partner. Ms. Schulman qualifies as an "audit committee financial expert." Professional and Other Experience: Polaris Partners, a venture capital firm, Managing Partner, New York (since 2014) LS Polaris Innovation Fund, a venture capital fund, Managing Director (since 2017) Mount Sinai Hospital, Director (since 2020) Harvard University Business School, Senior Lecturer (2014-2020 and since 2025) Lyndra Therapeutics, Inc., a biopharmaceutical company, Executive Chair (2019-2025) and CEO (2015-2019) Pfizer, Inc., a global biopharmaceutical company, Executive Vice President and General Counsel (2010-2013), and various other senior executive positions, including Business Unit Lead for Consumer Healthcare (2008-2013) DLA Piper, LLP (US), a global law firm, Partner and Counsel (1995-2008) Other Public Board Service: Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, Director and Non-Executive Chair (2014-Present) Fractyl Health, Inc., a therapeutics company, Director (2018-2025) SQZ Biotechnologies Company, a biotechnology company, Director (2014-2022) Cyclerion Therapeutics, a biopharmaceutical company, Director (2019-2021) Age: 65 Director Since: January 2026 Committees: Audit Finance Skills, Experiences and Attributes: CEO COO/Executive Leadership Finance/Capital Markets Healthcare Industry Technology Regulatory/Public Policy Governance and Sustainability Diversity Education: Wesleyan University, B.A. Yale University School of Law, J.D.